<DOC>
	<DOCNO>NCT00465621</DOCNO>
	<brief_summary>The purpose thie study compare safety IOP-lowering efficacy AL-37807 Ophthalmic Solution 0.05 % , 0.1 % 0.2 % dosed QD AM Xalatan dose QD PM Vehicle patient open-angle glaucoma ocular hypertension</brief_summary>
	<brief_title>Dose Response Study AL-37807 Ophthalmic Solution Patients With Open-Angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Openangle glaucoma ocular hypertension VA worse 0.60</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Open-angle glaucoma</keyword>
	<keyword>ocular hypertension</keyword>
</DOC>